DrugPatentWatch Database Preview
Immunoglobulin g - Biologic Drug Details
» See Plans and Pricing
Summary for immunoglobulin g
Tradenames: | 1 |
Patents: | 372 |
Applicants: | 1 |
BLAs: | 1 |
Suppliers: see list | 2 |
Recent Clinical Trials: | See clinical trials for immunoglobulin g |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for immunoglobulin g |
Recent Clinical Trials for immunoglobulin g
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Fondazione Schena | Phase 4 |
University of Bari | Phase 4 |
Sobi | Phase 3 |
Patent Text Search: US Patents for immunoglobulin g
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Octapharma Usa Inc | CUTAQUIG | immunoglobulin g | SOLUTION | 125668 | 1 | 2019-05-03 | Start Trial | Burroughs Wellcome, Inc. (Research Triangle Park, NC) | 1994-02-22 | search | ||
Octapharma Usa Inc | CUTAQUIG | immunoglobulin g | SOLUTION | 125668 | 1 | 2019-05-03 | Start Trial | Takeda Chemical Industries, Ltd. (Osaka, JA) | 1994-11-29 | search | ||
Octapharma Usa Inc | CUTAQUIG | immunoglobulin g | SOLUTION | 125668 | 1 | 2019-05-03 | Start Trial | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JA) | 1995-05-23 | search | ||
Octapharma Usa Inc | CUTAQUIG | immunoglobulin g | SOLUTION | 125668 | 1 | 2019-05-03 | Start Trial | W. R. Grace & Co. (New York, NY) | 1996-02-24 | search | ||
Octapharma Usa Inc | CUTAQUIG | immunoglobulin g | SOLUTION | 125668 | 1 | 2019-05-03 | Start Trial | Biotest-Serum-Institut GmbH (Frankfurt am Main, DE) | 1996-04-03 | search | ||
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for immunoglobulin g
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20140014403 | Start Trial |
Japan | 6347490 | Start Trial |
Norway | 20022468 | Start Trial |
Italy | 1179029 | Start Trial |
Australia | 2003226177 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for immunoglobulin g
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
2018 00018 | Denmark | Start Trial | PRODUCT NAME: PADELIPORFIN DIPOTASSIUM SALT; REG. NO/DATE: EU/1/17/1228 20171114 |
2018 00018 | Denmark | Start Trial | PRODUCT NAME: PADELIPORFIN DIPOTASSIUM SALT; REG. NO/DATE: EU/1/17/1228 20171114 |
C0002 | France | Start Trial | PRODUCT NAME: SEL DIPOTASSIQUE DE PADELIPORFINE; REGISTRATION NO/DATE: EU/1/17/1228 20171114 |
C/GB10/043 | United Kingdom | Start Trial | PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR))(HUMAN MONOCLONAL AMG 162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG 162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526 |
01830022 | Spain | Start Trial | PRODUCT NAME: PADELIPORFINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1228; DATE OF AUTHORISATION: 20171110; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1228; DATE OF FIRST AUTHORISATION IN EEA: 20171110 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |